77 results about "EGFR Antibody" patented technology

Provided is an antibody-drug conjugate for use in the treatment of cancer in which one or more KRAS mutants, particularly a KRAS G12V mutant, a KRAS G12D mutant, and a KRAS G12C mutant, are expressed. Also provided are a drug and a drug-linker conjugate for use in the antibody-drug conjugate.　The present inventors have produced an antibody-drug conjugate with which a heterocyclic compound represented by formula (II) and having an activity of inducing the decomposition of KRAS mutant proteins can be delivered to cancer in which EGFRs are expressed, the production being achieved by linking the compound to an anti-EGFR antibody. The present inventors have also discovered a drug-linker conjugate for use in the antibody-drug conjugate or a salt thereof. In cancer in which EGFRs are expressed, the antibody-drug conjugate induces the decomposition of one or more KRAS mutants, particularly a KRAS G12V mutant protein, a KRAS G12D mutant protein, and a KRAS G12C mutant protein, thereby inhibiting the KRAS mutants and exhibiting an anti-tumor effect.

The invention belongs to the field of biological medicine, and relates to an anti-EGFR monoclonal antibody, a bispecific antibody thereof, a pharmaceutical composition and application. Specifically, the invention relates to an anti-EGFR antibody or an antigen binding fragment thereof. The invention also relates to an anti-EGFR (Epidermal Growth Factor Receptor) and anti-MET (Methyl The anti-EGFR monoclonal antibody and the bispecific antibody provided by the invention both have good anti-tumor activity.

The present invention relates to combined use of an antibody-drug conjugate and an anti-EGFR antibody or an antigen-binding fragment thereof. Specifically, the present invention provides a pharmaceutical combination comprising an antibody-drug conjugate or a pharmaceutically acceptable salt thereof, a metabolite thereof, or a solvate thereof as a single agent, an anti-EGFR antibody or an antigen-binding fragment thereof, and optionally a platinum-based drug. Further provided is use of the pharmaceutical combination of the present application in preparing a drug for treating a tumor in a subject. Further provided is a method for treating a tumor in a subject, comprising administering to the subject the pharmaceutical combination of the present application.

The invention relates to a human peripheral blood cell immunotyping antibody combination and method based on flow cytometry. The antibody combination comprises an anti-CD3 antibody, an anti-CD4 antibody, an anti-CD8 antibody, an anti-EGFR antibody, an anti-CD25 antibody, an anti-CD127 antibody, an anti-CD45RA antibody, an anti-CCR7 antibody, an anti-CD27 antibody, an anti-PD-1 antibody, an antiTIGIT antibody and an anti-41BB antibody. The method comprises the following steps: mixing the antibody combination with a sample to be detected, incubating, performing flow cytometry detection to obtain detection data, and further judging the proportion and / or the number of target cell populations. According to the present invention, the optimal cell surface marker antibody combination is designed and obtained, the CAR-T cells in the sample are subjected to immune typing by using the 12-color antibody combination through the flow cytometry, the detection result is rapidly obtained, the CAR-T cell proportion of each phenotype is efficiently identified, and the method has high precision and high stability.

The present application provides a polypeptide as CDRs in an antibody light chain, light chain variable region or light chain, which is capable of constructing an antibody with CDRs in an antibody heavy chain, heavy chain variable region or heavy chain having binding affinity and / or specificity to different target proteins (antigens), the antibody retaining binding affinity and / or specificity to the target proteins (antigens) and biological activity. The present application also provides an anti-B7-H3 and / or EGFR antibody comprising the polypeptide as a light chain variable region or light chain.

Provided are a product and method for preventing or treating cancer by combining an anti-EGFR antibody or a fragment (for example, an antigen-binding fragment) thereof and a taxane drug, and related applications.

Disclosed herein are methods for treating a cancer in a subject in need thereof, comprising administering IL-2 conjugates in combination with an anti-EGFR antibody.

The present invention discloses an exosome fluorescence detection kit and application based on in-situ initiated ARGET ATRP signal amplification. The kit includes: carboxyl magnetic beads, BSA, EDC, NHS, BMP, EGFR antibody, Apt, FA, AA, CuBr2, ME6TREN, DMSO, and PBS buffer. The kit significantly improves the detection sensitivity based on the fluorescence performance of FA and the in-situ initiated ARGET ATRP signal amplification strategy. Through calculation, it is found that there is a good linear relationship between the logarithm of exosome concentration in the range of 5×10 4 ~5×10 9 exosomes / mL and the fluorescence signal intensity. The linear equation is: F(au) = 35956lgC exosomes -118474, and the correlation coefficient (R 2 ) is 0.997. The detection limit (LOD) of this method for detecting exosomes is 1.161×10 4 exosomes / mL (S / N = 3). Compared with the linear range and detection limit for detecting exosomes in other literatures, the fluorescence signal detection kit designed by the present invention has a wider detection range and a lower detection limit.

Provided herein is a method of treating a cancer comprising a KRAS G12C mutation in a patient, the method comprising administering to the patient sotorasib and an anti-epidermal growth factor receptor (EGFR) antibody in an amount effective to treat the cancer. Further provided is a method further comprising administering to the patient FOLFIRI (irinotecan, 5-FU and leucovorin).

Provided herein are methods of treating an EGFR-positive (EGFR+) cancer in a subject in need thereof comprising administering a bispecific gamma delta (γδ)-T cell engager (BS-GDTE) comprising a first antigen-binding domain that specifically binds to EGFR and a second antigen-binding domain that binds to human Vδ2.

The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods using such ADCs, and methods for making such ADCs.

The embodiment of the invention discloses a heavy chain variable region and a light chain variable region of an anti-EGFR monoclonal antibody and application of the heavy chain variable region and the light chain variable region. The invention relates to a heavy chain variable region and a light chain variable region of an anti-EGFR monoclonal antibody. The amino acid sequences of the heavy chain variable region are respectively shown as SEQ ID No.1-SEQ ID No.3; the amino acid sequences of the light chain variable region are respectively as shown in SEQ ID No. 4 to SEQ ID No. 6. The monoclonal anti-EGFR antibody provided by the invention retains the natural antibody diversity of a human immune system, has extremely low immunogenicity and broad spectrum, and can be efficiently combined with EGFR positive solid tumor cells. An anti-EGFR-CAR-T cell constructed based on the antibody can specifically recognize and kill EGFR positive solid tumor cells, overcomes the defects of an existing CAR-T cell therapy in solid tumor treatment, and has a good application prospect.

A conjugate having stability improved more than conventional conjugates without impairing the efficacy is provided by the present invention. The conjugate of the present invention is a conjugate of an anti-EGFR antibody site-specifically modified with a peptide and a chelating agent, wherein the chelating agent is chelated with a metal radionuclide, the peptide and the chelating agent are linked by a linker (L), and the linker (L) does not contain a thiourea bond.

This disclosure relates to anti-TROP2 / EGFR antibodies, and antibody drug conjugates derived therefrom, wherein the antibodies specifically bind to at least two different antigens EGFR and TROP2.

Provided herein are combinations comprising: (i) a compound having the name of 1-((1S, 1aS, 6bS)-5-((7-oxo-5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl) oxy)-1a, 6b-dihydro-1H-cyclopropyl [b] benzofuran-1-yl)-3-(2, 4, 5, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl) oxy)-1a, 6b-dihydro-1H-cyclopropyl [b] benzofuran-1-yl)-3-(2, 4, 6, 7, 8-tetrahydro-1, 8-naphthyridin-4-yl)-3-(2, 4, 6, 7 The invention relates to a compound A with a structure shown in a formula (I), or pharmaceutically acceptable salt, tautomer, stereoisomer, enantiomer, isotopic body, solvate or prodrug thereof, and an anti-EGFR antibody, such as panitumab. Compositions comprising the same; and methods of using these combinations and compositions in the treatment of cancer, such as colorectal cancer, pancreatic cancer, and non-small cell lung cancer. # imgabs0 #

The invention provides a polypeptide which can be used as a common light chain of a bispecific antibody to construct the bispecific antibody together with a heavy chain variable region or a heavy chain of an antibody with binding affinity and / or specificity to different target proteins. The invention also provides an anti-EGFR antibody, an anti-PD-L1 antibody and an EGFR * PDL1 bispecific antibody, wherein the antibodies comprise a common light chain variable region or a light chain.

Lentiviral vectors are provided that incorporate a nucleic acid construct encoding a modified EGFR. The nucleic acid constructs encode a modified EGFR that lacks EGFR domains I, II, and IV and that includes domain III and the EGFR transmembrane domain. Also provided are pharmaceutical compositions including the lentiviral vectors or cells transduced with the lentiviral vectors, and methods of treating a patient having cancer by administering the compositions and optionally subsequently administering to the patient an EGFR antibody to target the destruction of the cells expressing the modified EGFR.

The present invention belongs to the field of biomedicine and relates to an anti-EGFR monoclonal antibody, a bispecific antibody thereof, and a pharmaceutical composition and use thereof. Specifically, the present invention relates to an anti-EGFR antibody or an antigen-binding fragment thereof. The present invention further relates to an anti-EGFR-anti-Met bispecific antibody. The anti-EGFR monoclonal antibody and the bispecific antibody of the present invention have good anti-tumor activity.

The invention relates to the technical field of medical detection. The invention aims to provide a nano-probe for detecting the expression of an epidermal growth factor receptor of head and neck squamous carcinoma cells. The nano-probe is a nano-particle with a core-shell structure, the nano particle takes a nano Au particle as a core, and 4-mercaptobenzoic acid (4-MBA) is adsorbed on the surface of the Au core as a Raman signal internal reference molecule; according to the nanoparticle, SiO2 is used as a shell, and PEG and EGFR antibodies are linked to the SiO2 shell. According to the nanoprobe, head and neck squamous cell cancer cell and tissue imaging is researched by adopting a surface enhanced Raman spectroscopy technology, tumor cell and tissue EGFR expression images are drawn, and quantitative analysis and research are carried out. A rapid, visual and accurate new tool is provided for clinically detecting the squamous cell carcinoma of the head and neck and the EGFR expression condition of the squamous cell carcinoma of the head and neck.

The present disclosure relates to the use of a KRAS G12D inhibitor in combination with an anti-EGFR antibody in the manufacture of a medicament for the treatment of a solid tumor. In particular, the present disclosure relates to the use of a KRAS G12D inhibitor in combination with an anti-EGFR antibody, or an antigen-binding fragment thereof, in the manufacture of a medicament for the treatment of a solid tumor having a KRAS G12D mutation.

Relates to an antigen binding molecule specifically binding to EGFR and MUC1, and a drug conjugate and medical application thereof. Specifically, the invention relates to an anti-MUC1 antibody or an antigen-binding fragment thereof, an anti-EGFR antibody or an antigen-binding fragment thereof, an antigen-binding molecule specifically binding to EGFR and MUC1, conjugates of the anti-MUC1 antibody and the antigen-binding molecule and drugs, and medical applications of the anti-MUC1 antibody and the antigen-binding molecule.

The present invention provides antibody drug complexes for use in the treatment of cancers expressing G12D mutant KRAS. In addition, a drug-linker complex for use in the antibody drug complex is provided. The present inventors produce an antibody drug complex capable of delivering a heterocyclic compound represented by formula (I) to cancer, such as cancer expressing EGFR, by binding the heterocyclic compound to an antibody, such as an anti-EGFR antibody. In addition, a drug-linker complex used in the antibody drug complex or a salt thereof has been found. The antibody drug complex inhibits G12D mutant KRAS by inducing the decomposition of the G12D mutant KRAS protein in cancer, such as EGFR expressing cancer, and exhibits an anti-tumor effect.

Disclosed are methods for treating a subject suffering from cancer by administering to the subject an anti human HLA-G antibody in combination with an anti EGFR or an anti PD- 1 therapy.

Provided are an anti-EGFR antibody or an antigen-binding fragment thereof and a use thereof. The antibody or the antigen-binding fragment thereof comprises a heavy chain variable region and a light chain variable region. The heavy chain variable region comprises heavy chain complementarity determining regions HCDR1, HCDR2, and HCDR3. The light chain variable region comprises light chain complementarity determining regions LCDR1, LCDR2, and LCDR3, wherein LCDR1 comprises an amino acid sequence as shown in SEQ ID NO: 1, LCDR2 comprises an amino acid sequence as shown in SEQ ID NO: 2, and LCDR3 comprises an amino acid sequence as shown in SEQ ID NO: 3. Further provided are a nucleic acid molecule encoding the antibody or the antigen-binding fragment thereof, a vector and transformant for expressing the antibody or the antigen-binding fragment thereof, and a treatment and diagnosis / detection method and use of the antibody or the antigen-binding fragment thereof.

A non-immunogenic selection epitope may be generated by removing certain amino acid sequences of the protein. For example, a gene encoding a truncated human epidermal growth factor receptor polypeptide (EGFRt) that lacks the membrane distal EGF-binding domain and the cytoplasmic signaling tail, but retains an extracellular epitope recognized by an anti-EGFR antibody is provided. Cells may be genetically modified to express EGFRt and then purified without the immunoactivity that would accompany the use of full-length EGFR immunoactivity. Through flow cytometric analysis, EGFRt was successfully utilized as an in vivo tracking marker for genetically modified human T cell engraftment in mice. Furthermore, EGFRt was demonstrated to have cellular depletion potential through cetuximab mediated antibody dependent cellular cytotoxicity (ADCC) pathways. Thus, EGFRt may be used as a non-immunogenic selection tool, tracking marker, a depletion tool or a suicide gene for genetically modified cells having therapeutic potential.

This invention discloses an anti-EGFR antibody mutant with antioxidant properties and its applications, belonging to the field of biotechnology. To improve the antioxidant activity of antibodies and prevent oxidative degradation, existing anti-EGFR antibodies are analyzed and mutated to enhance their antioxidant performance and structural stability while maintaining superior affinity for the EGFR antigen. Furthermore, this mutant is assembled with an anti-c-Met antibody to form a heterodimer. The resulting bispecific antibody exhibits high affinity, greater structural stability, and stronger antioxidant capacity, thus showing promising market application prospects.

The present disclosure relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bel-xL, including compositions and methods using such ADCs, and methods for making such ADCs.

The invention discloses a USAG-1 recombinant protein targeted delivery system based on multi-enzyme logic gating and a preparation method, and mainly relates to crossing of biological medicine and nanotechnology. Comprising the following steps: S1, a C-terminal fusion nuclear localization sequence PKKKRKV of a recombinant USAG-1 protein expressed by CHO cells, and the purity of the recombinant USAG-1 protein is greater than or equal to 98%; s2, preparing core-shell structure nanoparticles, wherein the core is PLGA loaded BMP-2, and the drug loading capacity is 2.5-4.2 [mu] g / mg; the outer-layer lipid membrane is composed of DSPC / DSPG according to the ratio of 7: 3, and the surface embedded USAG-1 molecular density is greater than or equal to 1 * 10 / mu m < 2 >; s3, the surface co-modified EGFR antibody and the RGDfK peptide are connected through a thiol-maleimide bond and a PEG2000 spacer arm according to the molecular ratio of 1: 1.6 + / -0.2, the coding sequence of the recombinant USAG-1 is regulated and controlled by an MMP-9 response promoter, and the promoter is located in MMP-9gt; and the expression is activated at 20nM. The system has the beneficial effects that time-space precise delivery of the bone metabolism related protein USAG-1 is realized through a multi-enzyme logic gating mechanism, and the system is suitable for treatment of bone metabolism disorder diseases such as osteosarcoma and alveolar bone defect.

The invention relates to anti-Epidermal Growth Factor Receptor (EGFR) antibody drug conjugates (ADCs) which inhibit Bcl-xL, including compositions and methods of using said ADCs.